We report a case of paliperidone extended-release ( ER)-induced leukopenia and neutropenia in a female patient with schizoaffective disorder. We present a case study of a patient with schizoaffective disorder in a 50-year-old woman. Although these events are rare, they represent serious and life-threatening hematological side effects.
Matsuura, Hiroki Kimoto, Sohei Harada, Izumi Naemura, Satoshi Yamamuro, Kazuhiko Kishimoto, ToshifumiĪntipsychotic drug treatment can potentially lead to adverse events such as leukopenia and neutropenia. Lithium carbonate as a treatment for paliperidone extended-release-induced leukopenia and neutropenia in a patient with schizoaffective disorder a case report. The least squares mean change for Positive and Negative Risk of relapse was higher in subjects treated with paliperidone ER than in those treated with PP compared with a 10.9% decrease for paliperidone ER (58.5% vs 47.6%, respectively p = 0.048). Approximately 45% of enrolled subjects in both trials were stabilised and randomised to the DB relapse prevention phase. Categorical variables were evaluated using Chi-square and Fisher's exact tests. Between-group differences for continuous variables for change scores during the DB phase were assessed using analysis of co-variance models. Time to relapse between treatment groups was evaluated using a Cox proportional hazards model. Assessments included measures of time to relapse, symptom changes/functioning and treatment-emergent adverse events (TEAEs). This post hoc comparison of the long-term efficacy, safety and tolerability of maintenance treatment with paliperidone palmitate (PP) versus oral paliperidone extended release ( ER) used data from two similarly designed, randomised, double-blind (DB), placebo-controlled schizophrenia relapse prevention trials. Increasing availability and use of long-acting injectable antipsychotics have generated a need to compare these formulations with their oral equivalents however, a paucity of relevant data is available.
Markowitz, Michael Fu, Dong-Jing Levitan, Bennett Gopal, Srihari Turkoz, Ibrahim Alphs, Larry Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies.
0 kommentar(er)
